• Presented at ESMO (2023)

  • Collaborator: Pierre Fabre

  • Authors: E. Samalin, L. Lorenzon, C. Sarrauste de Menthière, L. Guéroult-Accolas, R. Paixão, C.Chaves Almagro, E. Pain, E. Martinelli

Approximately 500,000 people are diagnosed with colorectal cancer (CRC) every year in Europe [1]. Approximately 15 to 30% of these patients are initially diagnosed at a metastatic stage (mCRC), and 20% to 50% of patients with initially localized disease will relapse and present metastasis [2]. The
study objective is to better understand the unmet needs of mCRC patients’ during their care and treatment pathway, especially for patients with genetic alterations